



Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending December 31, 2023 [Japanese GAAP]

November 13, 2023
Listing: Tokyo Stock Exchange

Company name: Medical Data Vision Co., Ltd.
 Securities code: 3902 URL <https://www.mdv.co.jp/>
 Representative: (Title) President (Name) Hiroyuki Iwasaki
 Inquiries: (Title) Executive Officer and General Manager of Corporate Planning Division (Name) Masahiro Kihara Tel: +81-3-5283-6911

Scheduled date to file quarterly report: November 13, 2023

Scheduled date to commence dividend payments: -

Preparation of supplementary material on quarterly financial results : Yes

Holding of quarterly financial results briefing : Yes (for institutional investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted)

1. Consolidated financial results for the third quarter of the fiscal year ending December 31, 2023 (from January 1, 2023 to September 30, 2023)

(1) Consolidated operating results (cumulative) (Percentages indicate year-on-year changes)

	Net sales		Operating income		Ordinary income		Net income attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Third quarter of FY ending December 31, 2023	4,487	3.7	1,111	-4.6	1,063	-8.0	659	-15.0
Third quarter of FY ended December 31, 2022	4,327	-	1,165	-	1,156	-	775	-

(Note) Comprehensive income Third quarter of fiscal year ending December 31, 2023 644 million yen [-16.6%]
 Third quarter of fiscal year ended December 31, 2022 772 million yen [-%]

	Basic earnings per share		Diluted earnings per share	
	Yen		Yen	
Third quarter of FY ending December 31, 2023	17.27		17.26	
Third quarter of FY ended December 31, 2022	20.28		20.28	

(Note) 1. The Accounting Standard for Revenue Recognition (ASBJ Statement No. 29) and related implementation guidance have been applied from the beginning of the fiscal year ended December 2022. Consolidated earnings for the third quarter of the fiscal year ended December 2022, therefore, are the amount after applying such accounting standard and related implementation guidance, presenting no change from the previous corresponding period.

2. As of the end of the previous consolidated fiscal year, the provisional accounting treatment for business combinations was finalized, and the finalized provisional accounting treatment were reflected in the third quarter of the fiscal year ended December 2022.

(2) Consolidated financial position

	Total assets		Net assets		Equity-to-asset ratio	
	Millions of yen		Millions of yen		%	
As of September 30, 2023 (3Q FY2023)	5,571		4,024		70.5	
As of December 31, 2022 (FY2022)	4,897		3,606		71.8	

(Reference) Equity As of September 30, 2023 3,928 million yen
 As of December 31, 2022 3,515 million yen

2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen				
FY ended December 31, 2022	-	0.00	-	6.00	6.00
FY ending December 31, 2023	-	0.00	-		
FY ending December 31, 2023 (forecast)				6.50	6.50

(Note) Revision of the latest released dividend forecast : None

3. Consolidated earnings forecasts for the fiscal year ending December 31, 2023 (from January 1, 2023 to December 31, 2023)

(Percentages indicate year-on-year changes)

	Net sales		Operating income		Ordinary income		Net income attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	7,200	17.9	1,800	2.4	1,800	2.8	1,200	37.9	31.42

(Notes) Revision of the latest released earnings forecasts : None

* Notes

(1) Changes in significant subsidiaries during the three months ended September 30, 2023 (changes in specified subsidiaries resulting in changes in scope of consolidation) : None

Newly included: - companies (Company name) , Excluded: - companies (Company name)

(2) Application of special accounting treatment to the preparation of quarterly consolidated financial statements : None

(3) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations : Yes

(ii) Changes in accounting policies other than (i) above : None

(iii) Changes in accounting estimates : None

(iv) Restatement : None

(Notes) For more details, please refer to “(3) Notes to quarterly consolidated financial statements (Change in accounting policies) in 2. Quarterly consolidated financial statements and Key notes” on page 4 of the attached materials.

(4) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)	As of September 30, 2023	40,027,526 shares	As of December 31, 2022	40,027,526 shares
(ii) Number of treasury shares at the end of the period	As of September 30, 2023	1,830,678 shares	As of December 31, 2022	1,830,678 shares
(iii) Average number of shares outstanding during the period (cumulative quarterly period)	Third quarter of FY ending December 31, 2023	38,196,848 shares	Third quarter fiscal year ended December 31, 2022	38,246,880 shares

* Quarterly financial results reports are exempt from a quarterly review conducted by certified public accountants or an audit corporation.

* Proper use of earnings forecasts, and other special matters

The forward-looking statements, including earnings forecasts, contained in this material are based on information currently available to the Group and on certain assumptions deemed to be reasonable.